Preclinical studies and prospective clinical applications for bacteria-targeted imaging: the future is bright

Marjolein Heuker1 • Anna Gomes1 • Jan Maarten van Dijl1 • Gooitzen M. van Dam2 • Alexander W. Friedrich1 • Bhanu Sinha1 • Marleen van Oosten1

Abstract Bacterial infections are a frequently occurring and major complication in human healthcare, in particular due to the rapid increase of antimicrobial resistance and the emergence of pan-drug-resistant microbes. Current anatomical and functional imaging modalities are insufficiently capable of distinguishing sites of bacterial infection from sterile inflammation. Therefore, definitive diagnosis of an infection can often only be obtained by tissue biopsy and subsequent culture and, occasionally, a definite diagnosis even appears to be impossible. To accurately diagnose bacterial infections early, novel imaging modalities are urgently needed. In this regard, bacteria-targeted imaging is an attractive option due to its specificity. Here, different bacteria-targeted imaging approaches are reviewed, and their promising future perspectives are discussed.

Keywords Imaging • Infection • Bacteria • Tracer • Fluorescence • Radioisotope

Introduction

Bacterial infections are of major concern both in hospital and community settings worldwide. Although much fundamental knowledge has been gained about micro-organisms and antimicrobial therapy, infections remain responsible for substantial patient morbidity and mortality these days [1]. In addition, infections become increasingly difficult to treat due to the rapid increase of antimicrobial resistance and the spread of pan-drug-resistant microbes [2, 3]. Besides the fact that drug-resistant infections are difficult to treat, their associated healthcare costs are substantially higher. For example, 1–2% of the total joint arthroplasties will become infected, and the costs of treating such infections can amount up to $107,000 per case if caused by a resistant micro-organism. By comparison, the costs of treating infections with antibiotic-sensitive bacteria are substantially lower, revolving around $68,000 [4].

Despite a vast array of new technologies for the detection and typing of pathogens [5], diagnosing infections is often complex or even problematic. This results in a relatively, or even completely, blind management of infections. This complexity is a consequence of the fact that diagnosis is based on the combination of several non-specific signs and symptoms, systemic inflammation markers, and visualization with fairly unspecific imaging techniques [6–8]. A definite diagnosis of infectious disease, with evidence of infection and identification of the causative microbial species, can only be obtained by culture and/or molecular detection. Ideally, this involves obtaining material directly from the infective focus, which often requires tissue biopsy for deep-seated infections. This invasive diagnostic procedure takes many hours or even several days to yield an answer and, occasionally, it is not
even possible to obtain a representative biopsy. However, infections can be treated better when diagnosed accurately and early. Therefore, reliable and fast diagnostic processes are desirable [9].

Current imaging modalities to diagnose infectious disease comprise anatomical imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US), as well as functional imaging modalities, such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and scintigraphy. Unfortunately, these clinical imaging modalities by themselves are unable to differentiate bacterial infection from other infections (i.e., viral, fungal or parasitic), or from sterile inflammation [1, 10]. Ideally, an imaging modality would allow for a reliable detection of infection, differentiate infection from other causes of inflammation, and thereby circumvent the need of more invasive methods. Hence, a new imaging modality that allows for sensitive and specific imaging of bacterial infection, ideally even providing species and resistance information to guide optimal therapy, would be of high value in clinical practice. Such an imaging modality is most likely to be found in bacteria-targeted imaging approaches.

In this review, we present several bacteria-targeted imaging approaches and promising future perspectives of targeted imaging to diagnose infections.

**Methods**

A literature search was performed in PubMed, searching for publications in English, in the period between January 1980 and February 2016. The following search terms and variations thereof were used: *imaging, detection, specific, targeted, bacterial, radionuclide, optical* and/or *fluorescence*. Of the publications thus retrieved, only those that were aimed at bacteria-specific in vivo imaging, in animals or humans, were selected. CT, MRI, and US were not included, because in a separate search using the terms *computed tomography, magnetic resonance imaging*, and *ultrasound, targeted, specific, bacterial, detection*, articles describing in vivo bacteria-specific imaging with CT, MRI or US were identified. Only those tracers closest to clinical introduction are reported.

**Targeted imaging**

In recent years, an increasing interest in targeted imaging has been raised. Targeted imaging is based on an imaging agent, such as a radionuclide or fluorophore, coupled to a molecule (e.g., an antibody, an antibiotic, an antimicrobial peptide, a metabolizable compound, a bacteriophage, or a DNA/RNA-binding compound) that targets specific bacteria or other pathogens [9, 11]. Besides visualization of the site of infection, targeted imaging might also allow for the identification of the causative micro-organism. For additional information on the matter, we refer to the article of Mills et al. in this edition [11]. A more extensive review on targeted imaging was recently published by van Oosten et al. [9].

**Radionuclide imaging**

The functional non-targeted imaging modalities PET with 18F-fluoro-deoxy-glucose (FDG) and leukocyte scintigraphy are nowadays frequently used to track down sites of both infection and inflammation [12]. Imaging of infections with 18F-FDG–PET remains challenging due to the fact that all tissues with a high glucose uptake, such as brain, heart, malignancies, sterile inflammation and physiological wound healing, show increased FDG uptake [10]. Leukocyte scintigraphy partly overcomes this drawback as it allows to some extent the distinction between inflammation and infection by comparing images at different acquisition times [13]. However, a major drawback of leukocyte scintigraphy is that it is very laborious, since it involves the drawing of blood from the patient, harvesting and radio-labeling of leukocytes, and re-administering of the labeled leukocytes to the patient. Altogether, this procedure takes several hours. Other non-targeted radionuclide imaging techniques used to detect infections are 67Gallium-citrate imaging and bone scintigraphy [10]. In addition, two-step scintigraphy with streptavidin and 111Indium-biotin (111In-biotin) has been described by several research groups [14, 15]. The latter approach is based on the fact that streptavidin binds 111In-biotin with high affinity. However, this approach is unlikely to be bacteria-targeted as streptavidin accumulates at sites of infection as well as sites of inflammation [15].

The importance of non-invasive, specific, bacterial imaging in real time has become widely recognized. Most current knowledge on radionuclide-targeted imaging concerns 99mTechnetium-ciprofloxacin (99mTc-ciprofloxacin; Infecton®). In this regard, a large multi-centre clinical trial showed a sensitivity of 85.4 % and specificity of 81.7 % for detecting bacterial infections with 99mTc-ciprofloxacin [16]. Although the sensitivity seems promising, its specificity is relatively low. Several other studies showed similar concern about the specificity of this imaging agent [17–19]. Indeed, 18F-labeled ciprofloxacin did not allow for bacteria-specific imaging in humans [20]. PET scans in four patients with bacterial soft tissue infections showed increased uptake of the tracer in infected areas. However, the signal was not retained in infected tissue and vanished at similar elimination half-life as in healthy tissue. It was,
therefore, suggested that the radioactive signal was related to increased blood flow and vascular permeability in local infection [20]. Furthermore, there is a disadvantage of using ciprofloxacin due to the widespread resistance against this antibiotic [21, 22]. Besides $^{99m}$Tc-ciprolexacin, other antibiotic-based tracers used in patients are radionuclide-mediated tracer based on the nucleoside analog fialuridine [1-(2-deoxy-2-fluoro-D-arabino-furanosyl)-5-iodouracil; FIAU] has been evaluated in patients. Ubiquicidin is a peptide originally isolated from mouse macrophages, and synthetic fragments of ubiquicidin were shown to bind to both Gram-positive and Gram-negative bacteria as well as to fungi. Small clinical trials investigating radionuclide-mediated tracer based on the nucleoside analog fialuridine showed a sensitivity of 100 % and a specificity from 80 to 100 % for detection of bacterial and fungal infections [25–28]. Altogether, ten successful clinical studies have been reported on specific imaging of infections with radionuclide-mediated tracer based on the nucleoside analog fialuridine [29]. Importantly, $^{99m}$Tc-ubiquicidin allowed the detection of infections with 93.7 % accuracy and with a pooled data sensitivity and specificity of 97.5 and 89 %, respectively. No immunological side effects were observed. Furthermore, a radionuclide-mediated tracer based on the nucleoside analog fialuridine [1-(2-deoxy-2-fluoro-D-arabino-furanosyl)-5-iodouracil; FIAU] has been evaluated in patients. It was shown that FIAU is taken up by bacteria and incorporated into their DNA, while this was not the case in human cells. Successful visualization of bacterial infections using $^{124}$I-labeled FIAU has been reported, with apparently no false-positive or false-negative results in seven patients [30]. In contrast, a recent study investigating the use of $^{124}$I-FIAU to image prosthetic joint infections in patients did not establish a clear correlation between the infection status and imaging results [31]. Moreover, two clinical studies addressing the use of $^{124}$I-FIAU were terminated because of poor image quality, and a lack of correlation between FIAU uptake and bone biopsy results (clinicaltrials.gov: NCT01705496 and NCT01764919). Therefore, the future role of radionuclide-mediated tracer in imaging infection is currently unclear.

Another extensively described approach, which is hardly used anymore, is the imaging of infections with radiolabeled human polyclonal immunoglobulin (HIG) [32–34]. HIG was supposed to accumulate at sites of infection, but it is apparently not bacteria specific since the reported specificity ranges from 50 to 90 %. This compromised specificity is mainly due to the fact that inflammation often results in a false-positive signal.

Not explored in humans so far, but promising as bacteria-specific imaging agents, are compounds that are exclusively metabolized by bacteria. Recently, detection of bacteria with the sugar 6-[18F]-fluoromaltose ($^{18F}$-FM) has been reported [35]. Maltose and maltodextrins appear to be used as energy sources by the vast majority, if not all bacteria, since they express the maltodextrin transport complex in contrast to mammalian cells. $^{18F}$-FM, therefore, allows specific detection of all classes of bacteria and distinction of bacterial infection from other causes of inflammation. Another promising sugar for imaging purposes is sorbitol, which is a sugar alcohol mainly metabolized by Gram-negative bacteria, especially Enterobacteriaceae. 2-[18F]-fluoro-deoxy-sorbitol ($^{18F}$-FDS) was shown to allow for the specific detection of infections with Escherichia coli or Klebsiella pneumoniae in mice [36]. Importantly, $^{18F}$-FDS neither accumulated in healthy nor malignant mammalian cells in vitro. Thus, $^{18F}$-FM, $^{18F}$-FDS and other labeled compounds that can only be metabolized by bacteria have a high potential for bacteria-targeted imaging and clinical translation.

**Optical imaging**

Use of optical (i.e., fluorescence) tracers for bacteria-targeted imaging is an upcoming and interesting topic nowadays. Optical imaging of infections seems highly feasible and has some important advantages over radionuclide imaging, such as (1) a high resolution, (2) the absence of ionizing radiation and its associated risks, (3) the possibility of real-time visualization, and (4) lower cost [37–39]. An important drawback of optical imaging is its limited penetration depth of maximally 1–2 cm using near infrared tracers, and even less for tracers with shorter wavelengths. This limited penetration depth makes fluorescence imaging suitable mainly for imaging of surfaces and superficially located structures, and thus solely applicable in superficially located infections, such as soft tissue or superficial implant infections, or in intra-operative applications [40].

Over the past decades, much experience has been gained in optical imaging, for example in the visualization of tumors in image-guided surgery [41–43]. Indeed, tumor-specific intra-operative fluorescence imaging of ovarian cancer was shown feasible in 2011 by targeting the overexpressed folate receptor-α in patients [44]. Especially intra- and peri-operative fluorescence imaging is likely to be of great value and major improvements, such as enhanced visual information during surgery and, as a consequence, improved sensitivity and specificity and more.
optimal resection margins, can be expected. In addition, deeper signal penetration might be feasible with improvements in fluorescence dyes and charge-coupled device (CCD) cameras.

Despite the fact that many different fluorophores are available, only a few fluorophores are approved and tested for clinical use today, including fluorescein isothiocyanate (FITC; emission maximum 518 nm), indocyanine green (ICG; emission maximum 790 nm) and IRDye-800CW (emission maximum 800 nm). To date, bacteria-targeted fluorescence imaging is only described in a few in vivo studies, but with very promising results. First, Ning et al. showed specific uptake of fluorescently labeled maltodextrin by different bacterial strains and it was feasible to distinguish bacterial infections from sterile inflammation with high target-to-normal tissue (T/N) ratios in rats [45]. Second, Panizzi et al. used fluorescently and radiolabeled inactivated prothrombin, which binds to the staphylococcal coagulase produced by Staphylococcus aureus. These authors were able to make a distinction between S. aureus-induced versus Staphylococcus epidermidis-induced endocarditis, or sterile vegetations in mice [46]. Third, several research groups described the use of a fluorescent bis zinc (II)-dipicolylamine complex for infection imaging [47, 48]. This tracer attaches to the negatively charged membranes of bacteria. Unfortunately, the specificity of the fluorescent bis zinc (II)-dipicolylamine complex seems to be relatively low since this tracer also binds to negatively charged apoptotic cells [48]. Moreover, apoptotic cells are usually phagocytosed by macrophages which may further reduce the specificity. Lastly, non-invasive in vivo detection of infection caused by the Gram-positive bacterium S. aureus was shown using fluorescently labeled vancomycin [37]. Vancomycin-IRDye800CW (in short vanco-800CW) allowed the detection of S. aureus infection in vivo through several millimeters of tissue using a specialized CCD camera (Fig. 1). This was shown not only in a mouse model, but also in a human post-mortem model for biomaterial-associated infection. Vancomycin and IRDye-800CW are both approved substances for use in clinical practice, and it is therefore anticipated that vanco-800CW may be introduced safely for clinical use in the near future allowing for exploration of clinical applications. Whether the actual clinical application of vanco-800CW could be limited by increased vancomycin resistance in Gram-positive bacteria is currently unknown, but this is clearly a potential drawback of all antibiotic-based tracers [9].

Optoacoustic imaging

The relatively new detection technology of optoacoustic imaging has been recently suggested for use in clinical imaging. Like optical imaging, this technique is based on absorption of light of a certain wavelength by an appropriate fluorophore coupled to a specific targeting molecule. After absorption of light, the fluorophore molecules will undergo thermo-elastic expansion, which leads to the emission of ultrasonic pressure waves. In optoacoustic imaging, these ultrasonic waves are detected by specialized sensors [49]. Optoacoustic imaging allows for deeper visualization in tissue (around 11 cm in muscle tissue), since ultrasonic waves have longer wavelengths and deeper penetration than light [50]. This deeper penetration can particularly be valuable in the visualization of, e.g., bacterial infection of biomaterials or endocarditis. Next to these advantages, optoacoustic imaging offers a high resolution and high contrast comparable to that of MRI [49].

Other imaging modalities

Specific imaging with CT and MRI scanning has been reported for imaging of malignancies, using targeted modality-specific contrast agents [51, 52]. To the best of our knowledge, examples of bacteria-targeted imaging with CT or MRI in vivo have not yet been documented [9]. Neither were reports found addressing bacteria-specific targeting in vivo with the gas-filled microbubbles that are used as contrast agents in US [9]. Nevertheless, Anastasiadis et al. showed feasibility of a combined optical and acoustic evaluation in vitro, using targeted encapsulated gas bubbles for detection of early- and late-stage biofilm formation, potentially allowing for biofilm-specific imaging with US in vivo [53].

Smart activatable tracers

An exciting approach in the field of infection-targeted imaging is the detection of bacteria with the so-called “smart activatable tracers” (Fig. 2). Smart activatable tracers are optical tracers that are quenched in their normal state, and thus do not emit any signal. When the tracer encounters its target, the tracer is cleaved by bacterial enzymes, resulting in removal of the quencher. Subsequently, a fluorescence signal is emitted that can be detected. Imaging with smart activatable tracers usually results in a higher T/N ratio as compared to conventional tracers, and consequently in more efficient imaging. Successful use of smart activatable tracers has been reported for imaging tumors, as well as bacteria [54–56]. However, for infection imaging, results have so far only been obtained in animal studies. Kong et al. designed a smart activatable tracer based on a β-lactam ring, which is hydrolyzed by bacterial β-lactamases, leading to activation of the fluorophore [55]. Successful imaging with this tracer has been shown for Mycobacterium tuberculosis infection in mice. Although only M. tuberculosis infection
imaging has been described, this tracer might be applicable for all β-lactamase-producing bacteria. No T/N ratios have been reported yet for this β-lactam smart activatable tracer and, thus it is not clear whether the smart activatable tracer in this case indeed offers the increased T/N ratios required.

Furthermore, Hernandez et al. reported the non-invasive detection of *S. aureus* infection in mice, with an intravenously administered nuclease-activated tracer [56]. The quenched fluorescence oligonucleotide tracer is specifically activated by micrococcal nuclease (MN), a nuclease secreted by *S. aureus*. This tracer was proven to be MN- and thus *S. aureus*-specific, the mutated nuclease-deficient *S. aureus* showed a significantly lower signal. For this tracer, good T/N ratios have been reported.
Multi-modality tracers

A combination of imaging modalities allows for the concurrent application of the advantageous properties of each single modality, and thereby optimization of diagnosis. Multi-modality tracers are based on a targeting molecule, coupled to two or more imaging modality agents, such as radionuclides, fluorophores, CT contrast agents, MRI contrast agents, or microbubbles [57]. Such a multi-modality tracer allows for imaging of a target with one single tracer by two or more different imaging modalities simultaneously. For example, this potentially offers an opportunity for pre-operative detection of infection and tracking down its localization and, subsequently, it offers a possibility for optical visualization during invasive procedures. Such multi-modality tracers have been described for targeting inflammation (e.g., CD20 on B-cells, integrins and matrix metalloproteinases) [58]. Notably, a bacteria-targeted multi-modality tracer based on the antimicrobial peptide ubiquicidin has recently been described [59]. Ubiquicidin was conjugated to a radioisotope and fluorophore and this dual-modality tracer was able to detect *S. aureus* and *K. pneumoniae* infections in vivo using a combined imaging system. In our opinion, these multi-modality tracers are potentially of great value in bacterial infection imaging.

Photodynamic therapy

Besides using targeted modalities to optimize diagnosis of infection, targeted therapy could be used to improve infection treatment. In particular, targeted photodynamic therapy (PDT) could play an important role in the treatment of infections. PDT is based on excitation of photosensitive molecules with light of a certain wavelength, resulting in an optical signal as well as cytotoxic molecules that are capable of destructing the targeted cells [60, 61]. Treatment characteristics of this approach are promising, but untargeted PDT leads to damage of healthy tissue due to the non-specific uptake of photodynamic molecules, currently limiting this form of PDT to skin and dental infections [60, 62]. Targeted PDT might solve this drawback and was already shown to be successful in cancer treatment [61, 63]. It seems conceivable that targeted PDT could play an important role in the treatment of bacterial infections as well. Unfortunately, PDT would be limited to localized, easily accessible or superficial infections due to a limited penetration depth of available lasers. To date, there is little experience with targeted PDT in infections in vivo. Ragas et al. showed eradication of methicillin-resistant *S. aureus* (MRSA) infection in a murine burn wound model [64]. A cationic photosensitizer, which was topically administered, was used to target the bacteria. Although this technique eradicated MRSA, it is questionable whether this tracer is really “targeted”, since the photosensitizer binds to the negatively charged bacterial cell walls based on the cationic molecules, which probably would also have affinity for other negatively charged structures, such as apoptotic tissue. There is some more experience with targeted PDT in in vitro infection models. In this regard, feasibility has been shown for antibody-directed and antimicrobial peptides-directed PDT [65–67]. Suci et al. described successful targeted PDT based on a biotinylated photosensitizer and a biotinylated antibody specific for *Aggregatibacter actinomycetemcomitans*, coupled by streptavidin [68]. These results seem promising for the treatment of periodontal biofilms. Overall, PDT seems to be an interesting diagnostic and therapeutic application for locoregional infections.

Potential clinical applications of targeted imaging

Targeted imaging could enable earlier detection of infections, resulting in earlier institution of an accurate treatment. The more accurate treatment will subsequently represent a crucial element in the fight against bacterial...
resistance. Besides the application of targeted imaging in pre-operative diagnostics and post-operative follow-up of infections, it could also be used for intra-operative surgical guidance, theoretically leading to a more optimal resection of infected tissue and minimized damage in healthy tissue.

Potential use of tracers for different infections is outlined in Table 1.

**Necrotizing fasciitis**

Necrotizing fasciitis is a rapidly progressive infection of the deeper layers of skin and subcutaneous tissues, which requires immediate aggressive surgery and antibiotic therapy. To date, surgeons mainly rely on visual and tactile information during surgery. Infection borders of necrotizing fasciitis are difficult to recognize and can only be analyzed during surgery using frozen sections. Unfortunately, this is an indirect method giving information only about the small site of tissue where a biopsy was taken. Clearly, it is desirable to develop new methods that provide the needed information in real time and intra-operatively. Using targeted imaging, surgeons can be provided with extra visual information. In targeted optical imaging of ovarian cancer in patients, surgeons were able to detect small tumor spots of <1 mm [69]. Hypothetically, intra-operative targeted imaging can also result in better detection of infection, and more precise and radical resection, while sparing as much as possible healthy tissue. This may eventually lead to a better prognosis for patients with less mutilating outcomes. Presumably, targeted imaging would be of great value for necrotizing fasciitis-related surgery in the future.

**Septic arthritis**

Septic arthritis is most commonly caused by bacteria, but also fungi or viruses can be the causative agents. Notably, also sterile inflammatory diseases, such as rheumatoid arthritis or gout, are very common causes of arthritis. Arthritis caused by bacterial pathogens is often rapidly destructive, and thereby of the most fulminant subtype. In daily practice, the causative agent of arthritis is difficult to establish from the outside, and arthrocentesis is used to collect synovial fluid. Subsequent microbiological culturing is needed to find evidence of infection and to identify the responsible bacteria. Minimal-invasive targeted imaging techniques would be of great importance in this clinical

| Infection            | Common causative micro-organisms (>10 %)                                                                 | Potential tracers for detection                       | Remarks                                      |
|----------------------|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------|---------------------------------------------|
| Necrotizing fasciitis| *Streptococcus pyogenes*, other β-hemolytic streptococci, *Staphylococcus aureus*; (an) aerobic mixed flora, *Clostridium perfringens*, other clostridia* | CEF, CIP, FIAU, MALT, UBI, VAN                         |                                             |
| Septic arthritis     | *Staphylococcus aureus*, streptococci, *N. gonorrhoeae*                                                 | CEF, CIP, FIAU, FLER, MALT, NUC, PRO, UBI, VAN        |                                             |
| Infective endocarditis| *S. aureus*, coagulase negative staphylococci, viridans streptococci, enterococci, HACEK organisms* | CEF, CIP, FIAU, MAL, NUC, PRO, UBI, VAN               |                                             |
| Infected surgical meshes | *S. aureus*, coagulase negative staphylococci, streptococci, enterococci | CEF, CIP, FIAU, MALT, NUC, PRO, UBI, VAN             |                                             |
| Infected surgical grafts and meshes | *S. aureus*, coagulase negative staphylococci, streptococci, enterococci | CEF, CIP, FIAU, MALT, NUC, PRO, UBI, VAN             |                                             |
| Meningitis           | *Streptococcus pneumoniae*, *Neisseria meningitidis*, *Haemophilus influenzae*, *Listeria monocytogenes* | CEF, FIAU, MAL, UBI                                    | The tracer has to cross the blood–brain barrier |
| Bacteremia           | Miscellaneous                                                                                          | CEF, CIP, FIAU, MAL, NUC, PRO, SOR, UBI, VAN, BLA     |                                             |
| Pneumonia            | *Streptococcus pneumoniae*, *Haemophilus influenzae*, *S. aureus*. Hospital-acquired pneumonia: miscellaneous | CEF, CIP, FIAU, MAL, NUC, PRO, SOR, UBI, BLA         |                                             |

Tracers can be suitable in two possible ways, namely (1) detection of infection by targeting the vast majority of causative pathogens, or (2) by detection of particular species, which would have direct implications for the choice of therapy. Ideally, future approaches would offer both possibilities. Potentially usable tracers not only include the tracers in their current published structures but also future variants (e.g., modification from radiolabeled to optically labeled, or vice versa). Microorganisms and tracers are mentioned in alphabetical order.

* Micro-organisms that occur in less than 10 % of the cases, but are classically associated with the respective infection. The specific tracers listed are: 99mTc-ceftriaxone (CEF), 99mTc-ciprofloxacin/18F-ciprofloxacin (CIP), 123I-iodine-FIAU (FIAU), 18F-fleroxacin (FLER), 6-[18F]-fluoromaltose/maltodextrin-based optical tracer (MALT), activatable nuclease-targeted optical tracer (S. aureus-directed; NUC), prothrombin-based optical/radiolabeled tracer (PRO), 2-[18F]-fluoro-deoxy-sorbitol (SOR), 99mTc-ubiquicidin (UBI), vancomycin-IRDye 800CW (VAN), activatable β-lactamase-targeted optical tracer (BLA). HACEK organisms (fastidious Gram-negative bacilli): *Haemophilus* spp., *Aggregatibacter actinomycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens*, *Kingella kingae/Kingella denitrificans*
Infective endocarditis

Infective endocarditis (IE) causes serious morbidity and mortality (40% of all patients die in 1 year) [70]. Therefore, early and accurate diagnosis is crucial. Unfortunately, diagnosing IE remains a challenge in current clinical practice, due to its variable clinical presentation of both cardiac and extra-cardiac manifestations. Diagnosis of IE is largely based on the modified Duke criteria, of which blood cultures and echocardiography are cornerstones [71]. These criteria have only a sensitivity and specificity of around 80% when no artificial material is involved [71], and the ultimate diagnosis has still to be made by expert clinical judgement. Echocardiography has been shown to miss life-threatening complications in 30% of patients [72]. In addition, blood cultures show no causative micro-organism in up to 31% of all cases of IE [73], partly due to prior antimicrobial therapy. This poses considerable diagnostic and therapeutic dilemmas in clinical practice, as anatomic information guides indication and timing of surgical treatment. Furthermore, it is essential to determine the causative micro-organism and its resistance pattern to implement appropriate antimicrobial therapy. Here, opportunities for improved imaging are, obviously, highly desirable. Promising results in this direction have been published using conventional 18F-FDG–PET/CT and leukocyte scintigraphy [74]. These functional techniques use, respectively, 18F-FDG as tracer and PET/CT for detection, or radiolabeled white blood cells (e.g., with 99mTc-HMPAO) as tracers and SPECT/CT for detection. Pizzi et al. have reported the largest study to date evaluating 18F-FDG–PET/CT in endocarditis. Their results show that the largest group of 50 patients with possible endocarditis (54%) could be reduced to 5 (5%) [75]. Furthermore, Rouzet et al. compared both imaging techniques in IE, and their results mainly indicate that 18F-FDG–PET/CT is more sensitive, whereas leukocyte scintigraphy is more specific [76]. However, even when taking most recent (non-specific) imaging developments into account [74], more specific diagnosis of IE could prove critical in a vast amount of remaining cases with diagnostic uncertainty. In addition, opportunities to accelerate accurate diagnosis and treatment could prove lifesaving. Therefore, targeted imaging represents an appealing option for IE diagnosis. For example, targeted imaging could disclose the pathogenic bacterium in cases of negative blood cultures, so that adequate antibiotic therapy can be given. Besides, targeted imaging could point towards additional and distant sites of cardiac infection, which should be taken into account in the individualized therapy plan. On top of this, intra-operative targeted imaging could visualize the exact borders of infected tissue of which radical resection could potentially improve patient outcome. This is likely to be highly important in this condition since it is mandatory to immediately implant prosthetic material in the area of infected tissue.

Infected surgical meshes

Surgical meshes are commonly used to support tissue. In particular, these meshes are useful for permanent support in the repair of abdominal and inguinal hernias. Occasionally, a wound infection will occur after surgical intervention and, on longer term, intestinal-cutaneous fistulas can occur after abdominal surgery. Often it is difficult to determine whether and to what extent implanted meshes are involved in these infectious processes. This is highly relevant to predict prognosis and determine most optimal therapy. Targeted imaging could provide information on (1) whether the mesh is involved in the infectious process, and (2) what is the causing bacterial species. Due to the minimal-invasive targeted imaging technique, a more invasive technique, with ultimately preventive removal of the mesh, may be avoided.

Infected vascular grafts

Superficial (i.e., dialysis shunts) and deeper seated (e.g., aortic aneurysm repair) vascular graft infections are responsible for high patient morbidity and mortality, if not treated immediately [77]. Frequently, only the outside of the graft is infected resulting in negative blood cultures. Nowadays, 18F-FDG–PET-scan and/or leukocyte scintigraphy are used for the diagnosis of vascular graft infections in addition to the CT-scan. Both give information about inflammatory activity, in addition to the anatomic information derived from a simultaneous and/or separate CT-scan. However, infection cannot be reliably distinguished from sterile inflammation or physiological wound healing using 18F-FDG–PET nor CT-scan. Therefore, early infected vascular grafts cannot always be readily detected [78]. Also, notwithstanding its high sensitivity (91%), 18F-FDG–PET is not an ideal imaging approach for detection of infected vascular grafts since its specificity is rather low (64%) [77]. Leukocyte scintigraphy seems to allow for a higher specificity, especially early post-operatively, and is recommended if the CT-scan is inconclusive [79, 80]. Nevertheless, a non-invasive specific targeted imaging technique is highly desirable for detection of infected vascular grafts. The most important advantage of such a
targeted approach is that an invasive surgical procedure is not needed to diagnose bacterial infection, to determine which vascular grafts are involved in infection, and to what extent these grafts are affected. Targeted imaging that allows for determination of the causative bacterial pathogen would highly aid in directing optimal therapy. This would be especially helpful in detecting fastidious microorganisms that cannot be routinely cultured, such as Coxiella burnetii. Besides, intra-operative targeted imaging could aid for determining the extent of infected tissue and grafts, and for determining the most optimal resection borders.

**Meningitis**

The diagnosis of meningitis is currently based on blood tests (i.e., C-reactive protein and complete blood count), blood cultures, and most importantly examination of the cerebrospinal fluid (CSF). CSF should be obtained of every patient with a suspicion of meningitis to identify the causative micro-organism unless a lumbar puncture is contraindicated (e.g., brain tumor, abscess, or a high intracranial pressure). In selected patients a CT scan or MRI scan is recommended prior to lumbar puncture to check for the existence of contraindications, which delays the actual puncture. As it is of great importance to treat meningitis quickly with antibiotics, in these cases broad-spectrum antimicrobial treatment is commonly initiated before lumbar puncture to prevent treatment delay. Unfortunately, this early start of antibiotic treatment often interferes with finding the causative agent, whereas culture of CSF that is obtained after start of antibiotic treatment has a substantially lower sensitivity. A sensitive imaging modality to detect meningitis at an early stage and to discriminate between different causative pathogens would be highly desirable [81]. Especially the new hybrid PET/MRI approach seems very promising for distinguishing meningitis from other pathologies such as abscesses and encephalitis [82–84]. This might even allow a distinction of meningitis caused by viruses from bacterial meningitis by pattern recognition. Bacteria-targeted PET tracers, such as 18F-FDS or 18F-FM, which detect a subset or all bacterial species, could more clearly distinguish bacterial infections from other pathologies, and especially tracers that identify particular bacterial groups or even species could enable quick and more accurate treatment. An extra challenge might be found in designing tracers that reliably pass the blood–brain barrier upon intravenous administration. Also, it remains to be seen whether the bacterial load in meningitis is high enough for detection with the current PET cameras, which have a relative low resolution (3–4 mm). Clearly, a rapid and highly sensitive test for the presence of bacteria using fluorescence tracers could improve diagnostic accuracy and accelerate diagnosis in patients where CSF has been obtained. This option could make use of optical smart activatable tracers and dedicated sensors which might be even used as bedside tests.

**Bacteremia**

The gold standard for diagnosis of bacteremia (in case of sepsis or endocarditis) is the isolation of micro-organisms from a blood culture. Ideally, blood cultures are obtained prior to antimicrobial therapy. Unfortunately, it takes several days of culture until the causative micro-organism with its matching resistance pattern is identified. In case of infection with a fastidious micro-organism or antibiotic usage prior to the blood culture collection, identification of the bacterial species can be problematic. Real-time detection of bacteria in the blood stream of a patient would, therefore, be of great value. In particular, optical targeted imaging might be ideal for this application, since this makes real-time bedside measurements feasible. For instance, the diagnosis of infection could potentially be made much faster by implementing continuous measurement systems. This could involve optical smart activatable tracers and dedicated sensors. Subsequently, this would also allow for treatment follow-up, to detect whether the bacterial load in the blood stream is decreasing.

**Pneumonia**

Currently, diagnosis of pneumonia comprises clinical symptoms and signs, radiography and sputum culture. Radiography reveals in most cases pulmonary infiltrates, but differentiation between infection and other causes of pulmonary infiltration (e.g., atelectasis, infarction, hemorrhage, acute respiratory distress syndrome and malignancy) remains difficult with a specificity of only 33–70 % [85, 86]. Sputum culture, or even more optimal bronchoalveolar sample culture, can provide relevant information, but it takes several days before a reliable identification of the causative agent and its drug-resistance profile is available, if at all. Besides, representative respiratory material is often not obtainable due to the clinical situation of the patient. As a consequence, physicians substantially overtreat patients by early empirical initiation of broad-spectrum antibiotic therapy. Thus, there is currently an unmet need for fast and accurate diagnosis of pneumonia and identification of its causative agent to allow narrow-spectrum treatment and avoid unnecessary antibiotic usage. Development of a set of infection-targeted optical tracers for direct detection of pneumonia is a highly promising approach. First clinical trials on bacteria-targeted imaging are currently initiated at the Royal Infirmary in Edinburgh to detect bacterial pneumonia using a bronchoscope.
combined with confocal laser endomicroscopy (clinicaltrials.gov: NCT02558062 and NCT02491164). Potentially, this approach can visualize pneumonia in situ, not only providing direct cues about the presence and localization of pneumonia, but also offering the possibility of focused sample collection for subsequent microbiological analysis (i.e., microscopy, culture or molecular analysis).

Conclusion

Bacteria-targeted imaging is of significant upcoming interest. Progress has been made in the development of specific tracers, as well as in the development of imaging modalities to visualize infection. It remains difficult to predict which tracers or modalities will prove most appropriate for clinical use, but it is to be expected that some of the approaches described in this review will eventually find their place in routine clinical diagnostic settings. The further implementation of new imaging techniques, such as multi-modality imaging or optoacoustic imaging, and smart activatable tracers, holds even greater promise for quick and accurate detection of infections. This may ultimately be extended to antibacterial therapy in case of targeted PDT. We thus conclude that bacteria-targeted imaging has a bright future.

Author contributions M Heuker, A Gomes and M van Oosten: Imaging has a bright future.

Conflict of interest M Heuker, A Gomes, JM van Dijl, GM van Dam, AW Friedrich and B Sinha: Content planning, manuscript writing and editing.

Compliance with ethics guidelines

Conflict of interest M Heuker, A Gomes, JM van Dijl, GM van Dam, AW Friedrich, B Sinha and M van Oosten have no conflict of interest to disclose.

Human and animal studies This article does not contain any unpublished studies with human or animal subjects performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Love C, Palestro CJ (2004) Radionuclide imaging of infection. J Nucl Med Technol 32(2):47–57
2. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Werthem HF, Sumpradit N et al (2013) Antibiotic resistance—the need for global solutions. Lancet Infect Dis 13(12):1057–1098
3. World Health Organization (2016) The evolving threat of antimicrobial resistance—options for action. http://apps.who.int/iris/bitstream/10665/44812/1/9789241503181_eng.pdf. Accessed 25 February 2016
4. Parviz J, Pawasarat IM, Azam KA, Joshi A, Hansen EN, Bozic KJ (2010) Periprosthetic joint infection: the economic impact of methicillin-resistant infections. J Arthroplasty 25(6 Suppl):103–107
5. Sabat AJ, Budimir A, Nashev D, Sa-Leao R, van Dijl J, Laurent F et al (2013) Overview of molecular typing methods for outbreak detection and epidemiological surveillance. Euro Surveill 18(4):20380
6. Carek PJ, Dickerson LM, Sack JL (2001) Diagnosis and management of osteomyelitis. Am Fam Physician 63(12):2413–2420
7. Hatzenbuehler J, Pulling TJ (2011) Diagnosis and management of osteomyelitis. Am Fam Physician 84(9):1027–1033
8. Trampuz A, Zimmerli W (2006) Diagnosis and treatment of infections associated with fracture-fixation devices. Injury 37(Suppl 2):S59–S66
9. van Oosten M, Hahn M, Crane LM, Pleijhuis RG, Francis KP, van Dijl JM et al (2015) Targeted imaging of bacterial infections: advances, hurdles and hopes. PEMS Microbiol Rev 39(6):892–916
10. Love C, Tomás MB, Tronco GG, Palestro CJ (2005) FDG PET of infection and inflammation. Radiographics 25(5):1357–1368
11. Mills B, Bradley M, Dhalwal K (2016) Optical imaging of bacterial infections. Clin Transl Imaging 4:163–174. doi:10.1007/s40336-016-0180-0
12. El-Haddad G, Zhuang H, Gupta N, Alavi A (2004) Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 34(4):313–329
13. Glaudemans AW, Galli F, Pacilio M, Signore A (2013) Leukocyte and bacteria imaging in prosthetic joint infection. Eur Cell Mater 25:61–77
14. Fogarasi M, Pullman J, Winnard TJ, Hnatowich DJ, Rusckowski M (1999) Pretargeting of bacterial endocarditis in rats with streptavidin and 111In-labeled biotin. J Nucl Med 40(3):484–490
15. Lazzeri E, Pauwels EK, Erba PA, Volterriani D, Manca M, Bodei L et al (2004) Clinical feasibility of two-step streptavidin111In-biotin scintigraphy in patients with suspected vertebral osteomyelitis. Eur J Nucl Med Mol Imaging 31(11):1505–1511
16. Britton KE, Wareham DW, Das SS, Solanki KK, Amaral H, Bhurtnagar A et al (2002) Imaging bacterial infection with 99mTc-ciprofloxacin (Infecton®). J Clin Pathol 55(11):817–823
17. Sarda L, Crémieux AC, Lebellec Y, Meulemans A, Lebahi R, Hayem G et al (2003) Inability of 99mTc-ciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases. J Nucl Med 44(6):920–926
18. Siaens RH, Rennen HJ, Boereman OC, Dierckx R, Slegers G (2004) Synthesis and comparison of 99mTc-enrofloxacin and 99mTc-ciprofloxacin. J Nucl Med 45(12):2088–2094
19. Dumarey N, Blocklet D, Appelboom T, Tant L, Schoutens A (2002) Infection is not specific for bacterial osteo-articular infective pathology. Eur J Nucl Med Mol Imaging 29(4):530–535
20. Langer O, Brunner M, Zeitering M, Zieliger S, Müller U, Dobrozemsky G et al (2004) In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging 32(2):143–150
21. Hall AV, Solanki KK, Vinjamuri S, Britton KE, Das SS (1998) Evaluation of the efficacy of 99mTc-Infecton, a novel agent for detecting sites of infection. J Clin Pathol 51(3):215–219
22. Malamitsi J, Giamarellou H, Kanellakopoulou K, Dounis E, Grecka V, Christakopoulos J et al (2003) Infecton®: a 99mTc-ciprofloxacin radiopharmaceutical for the detection of bone infection. Clin Microbiol Infect 9(2):101–109
57. Lee S, Chen X (2009) Dual-modality probes for in vivo molecular imaging. Mol Imaging 8(2):87–100

58. Azhdarinia A, Ghosh P, Ghosh S, Wilganowski N, Sevick-Muraca EM (2012) Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis. Mol Imaging Biol 14(3):261–276

59. Welling MM, Bunschoten A, Kuil J, Nefissens RG, Beekman FJ, Buckle T et al (2015) Development of a hybrid tracer for SPECT and optical imaging of bacterial infections. Bioconjug Chem 26(5):839–849

60. Rajesh S, Koshi E, Philip K, Mohan A (2011) Antimicrobial photodynamic therapy: an overview. J Indian Soc Periodontol 15(4):323–327

61. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H (2011) Cancer cell-selective in vivo near infrared photosensitization targeting specific membrane molecules. Nat Med 17(12):1685–1691

62. Kharkwal GB, Sharma SK, Huang YY, Dai T, Hamblin MR (2011) Photodynamic therapy for infections: clinical applications. Lasers Surg Med 43(7):755–767

63. Mitsunaga M, Nakajima T, Sano K, Kramer-Marek G, Choyke PL, Kobayashi H (2012) Immediate in vivo target-specific cancer cell death after near infrared photoinmunotherapy. BMC Cancer 12:345

64. Ragas X, Sanchez-Garcia D, Ruiz-Gonzalez R, Bacigaluppi M, MR Hamblin, Nonell S (2010) Cationic porphycenes as potential photosensitizers for antimicrobial photodynamic therapy. J Med Chem 53(21):7796–7803

65. Bhatti M, MacRobert A, Henderson B, Shepherd P, Cridland J, Wilson M (2000) Antibody-targeted lethal photosensitization of Aggregatibacter actinomycetemcomitans biofilm. Antimicrob Agents Chemother 44(10):2615–2618

66. Demidova TN, Hamblin MR (2004) Photodynamic therapy targeted to pathogens. Int J Immunopharmacol Pharmacol 17(3):245–254

67. Dosselli R, Tampieri C, Ruiz-Gonzalez R, De Munari S, Ragas X, Sanchez-Garcia D et al (2013) Synthesis, characterization, and photoinduced antibacterial activity of porphyrin-type photosensitizers conjugated to the antimicrobial peptide apidaecin 1b. J Med Chem 56(3):1052–1063

68. Suci P, Kang S, Ntziachristos V, Hollema H et al (2011) Photodynamic therapy for infections: clinical applications of Porphyromonas gingivalis. Antimicrob Agents Chemother 55(10):2615–2618

69. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Suci P, Kang S, Gmur R, Douglas T, Young M (2010) Targeted Dosselli R, Tampieri C, Ruiz-Gonzalez R, De Munari S, Ragas X, Sanchez-Garcia D et al (2013) Synthesis, characterization, and photoinduced antibacterial activity of porphyrin-type photosensitizers conjugated to the antimicrobial peptide apidaecin 1b. J Med Chem 56(3):1052–1063

70. Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG Jr, Bayer AS et al (2009) Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study. Arch Intern Med 169(5):463–473

71. Li JS, Sexton DJ, Mick N, Ntetsis R, Fowler VG Jr, Ryan T et al (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30(4):633–638

72. Habets J, Tanis W, van Herwerden LA, van den Brink RB, Mali WP, de Mol BA et al (2014) Cardiac computed tomography angiography results in diagnostic and therapeutic change in prosthetic heart valve endocarditis. Int J Cardiovasc Imaging 30(2):377–387

73. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F et al (2015) 2015 ESC Guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European society of cardiology (esc) endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36(44):3075–3128

74. Gomes A, Glaudemans AWJM, Touw DJ, van Melle JP, Willems TP, Maass AH et al (2016) Diagnostic value of imaging in infective endocarditis: a systematic literature review and a proposal of an updated diagnostic work-up. Lancet Infect Dis (in press)

75. Pizzi MN, Roque A, Fernandez-Hidalgo N, Cuellar-Calabria H, Ferreira-Gonzalez I, Gonzalez-Alujas MT et al (2015) Improving the diagnosis of infective endocarditis in prosthetic valves and intracardiac devices with 18F-fluorodeoxyglucose positron emission tomography/computed tomography angiography: initial results at an infective endocarditis referral center. Circulation 132(12):1113–1126

76. Rouzet F, Chequer R, Benali K, Lepage L, Ghodbane W, Duval X et al (2014) Reproducible performance of 18F-FDG PET and radiolabeled leukocyte scintigraphy for the diagnosis of prosthetic valve endocarditis. J Nucl Med 55(12):1980–1985

77. Fukushima K, Ishida Y, Higashi M, Tsunekawa T, Oguno H, Minatoya K et al (2005) Detection of aortic graft infection by 18F-fluorodeoxyglucose positron emission tomography: comparison with computed tomographic findings. J Vasc Surg 42(5):919–925

78. Keidar Z, Pirmasashvili N, Leiderman M, Nitecki S, Israel O (2014) 18F-FDG uptake in noninfectious vascular grafts: incidence, patterns, and changes over time. J Nucl Med 55(3):392–395

79. Bruggink JL, Slart RH, Pol JA, Reijnen MM, Zeebregts CJ (2011) Current role of imaging in diagnosing aortic graft infections. Semin Vasc Surg 24(4):182–190

80. Erba PA, Leo G, Sollini M, Tascini C, Boni R, Berchiolli RN et al (2014) Radiolabelled leucocyte scintigraphy versus conventional radiological imaging for the management of late, low-grade vascular prosthetic infections. Eur J Nucl Med Mol Imaging 41(2):357–368

81. Iovino F, Seinen J, Henriques-Normark B, van Dijl JM (2016) How does Streptococcus pneumoniae invade the brain? Trends Microbiol 24(4):307–315

82. Nensa F, Beiderwellen K, Heusch P, Wetter A (2014) Clinical applications of PET/MRI: current status and future perspectives. Diagn Interv Radiol 20(5):438–447

83. Yang ZL, Zhang LJ (2016) PET/MRI of central nervous system: current status and future perspective. Eur Radiol. doi:10.1007/s00330-015-4202-5

84. Bever T, Freudenberg LS, Czernin J, Townsend DW (2011) The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond. Insights Imaging 2(3):235–246

85. Fábregas N, Ewig S, Torres A, El-Ebiary M, Ramirez J, de La J Respir Crit Care Med 165(7):867–903